Biomea Fusion’s (BMEA) “Market Outperform” Rating Reaffirmed at Citizens Jmp

Biomea Fusion (NASDAQ:BMEA)‘s stock had its “market outperform” rating reaffirmed by investment analysts at Citizens Jmp in a note issued to investors on Wednesday, Benzinga reports. They currently have a $7.00 target price on the stock.

BMEA has been the topic of several other research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Biomea Fusion in a research note on Monday, September 28th. Wall Street Zen raised Biomea Fusion from a “sell” rating to a “hold” rating in a research note on Monday, October 5th. Citigroup reaffirmed a “market outperform” rating on shares of Biomea Fusion in a report on Wednesday, September 30th. Brookline Capital Markets initiated coverage on Biomea Fusion in a research report on Wednesday, October 7th. They set a “buy” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Biomea Fusion in a report on Wednesday. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $7.60.

Biomea Fusion Trading Down 34.2%

Shares of BMEA traded down $0.43 during trading hours on Wednesday, reaching $0.83. The company had a trading volume of 7,741,902 shares, compared to its average volume of 1,449,558. The firm has a 50 day simple moving average of $1.53 and a 200-day simple moving average of $1.47. The company has a market capitalization of $60.09 million, a price-to-earnings ratio of -2.90 and a beta of -0.28. Biomea Fusion has a 12-month low of $0.81 and a 12-month high of $2.24.

Biomea Fusion (NASDAQ:BMEA) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.10. Sell-side analysts forecast that Biomea Fusion will post -0.71 earnings per share for the current year.

Institutional Investors Weigh In On Biomea Fusion

Institutional investors and hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC increased its position in Biomea Fusion by 174.3% during the first quarter. Renaissance Technologies LLC now owns 1,312,798 shares of the company’s stock worth $2,009,000 after buying an additional 834,179 shares in the last quarter. BlackRock Inc. purchased a new position in shares of Biomea Fusion during the second quarter valued at approximately $1,052,000. GSA Capital Partners LLP acquired a new stake in Biomea Fusion during the second quarter worth approximately $318,000. ADAR1 Capital Management LLC acquired a new stake in Biomea Fusion during the second quarter worth approximately $64,000. Finally, Rathbones Group PLC purchased a new stake in Biomea Fusion in the 1st quarter worth approximately $57,000. Hedge funds and other institutional investors own 96.72% of the company’s stock.

Trending Headlines about Biomea Fusion

Here are the key news stories impacting Biomea Fusion this week:

• Positive Sentiment: BMF-650 demonstrated early weight-loss activity. Across five multiple-ascending-dose cohorts, participants showed consistent weight reduction over four weeks. The highest-dose group reached 400 mg once daily following a single one-week titration period. Biomea Fusion Announces Phase 1 Results for BMF-650
• Positive Sentiment: Analysts remain bullish. Citizens JMP reaffirmed its “Market Outperform” rating with a $7 price target, while HC Wainwright reaffirmed its “Buy” rating and set a $4 target. Both targets imply substantial upside from recent trading levels.
• Neutral Sentiment: Management is highlighting the possibility of separating weight loss from gastrointestinal side effects. The company discussed BMF-650’s potential to offer an oral GLP-1 treatment with improved tolerability, but this remains an investigational hypothesis requiring additional clinical testing. Biomea Fusion discusses BMF-650 Phase I results
• Negative Sentiment: The stock fell after the Phase 1 data release. Investors may have been disappointed that the results are based on a small, short-duration, early-stage study and do not yet establish BMF-650’s durability, comparative efficacy, or long-term safety. The market reaction outweighed the favorable analyst commentary. Biomea reports Phase 1 weight-loss data

About Biomea Fusion

Biomea Fusion, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for serious diseases with significant unmet medical needs. The company’s research platform is centered on covalent chemistry, an approach designed to create potentially durable interactions between medicines and their biological targets.

Biomea’s lead investigational product is icovamenib, formerly known as BMF-219, an oral covalent menin inhibitor. The company has evaluated icovamenib in oncology indications, including certain blood cancers, and is also investigating its potential in metabolic diseases such as diabetes.